Item type: | Article | ||||
---|---|---|---|---|---|
Journal or Publication Title: | Nature Reviews Gastroenterology & Hepatology | ||||
Publisher: | Nature | ||||
Place of Publication: | NEW YORK | ||||
Volume: | 17 | ||||
Number of Issue or Book Chapter: | 9 | ||||
Page Range: | pp. 557-588 | ||||
Date: | 2020 | ||||
Institutions: | Medicine > Lehrstuhl für Pathologie | ||||
Identification Number: |
| ||||
Keywords: | BILIARY-TRACT CANCER; EPITHELIAL-MESENCHYMAL TRANSITION; PRIMARY SCLEROSING CHOLANGITIS; MIXED HEPATOCELLULAR-CHOLANGIOCARCINOMA; HUMAN INTRAHEPATIC CHOLANGIOCARCINOMA; ISOCITRATE DEHYDROGENASE 1; CIRCULATING TUMOR-CELLS; STEM-LIKE PLASTICITY; BILE-DUCT CANCER; PERIHILAR CHOLANGIOCARCINOMA; | ||||
Dewey Decimal Classification: | 600 Technology > 610 Medical sciences Medicine | ||||
Status: | Published | ||||
Refereed: | Yes, this version has been refereed | ||||
Created at the University of Regensburg: | Yes | ||||
Item ID: | 49925 |
Abstract
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for similar to 15% of all primary liver cancers and similar to 3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and ...
Abstract
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for similar to 15% of all primary liver cancers and similar to 3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing similar to 2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin, genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments. Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted.
Metadata last modified: 11 Oct 2021 12:46